Tiny biotech ham­mered as lead drug fails a key PhII study

Sen­so­ri­on saw its shares col­lapse on Mon­day when the tiny French biotech re­port­ed that its on­ly clin­i­cal-stage drug had failed the pri­ma­ry end­point on a key Phase II study — its most ad­vanced test for the ther­a­py.

Found­ed with an eye to de­vel­op­ing new drugs for hear­ing loss, Sen­so­ri­on says SENS-401 (araza­setron) failed to reach sta­tis­ti­cal sig­nif­i­cance for im­prov­ing hear­ing loss com­pared to place­bo in the 115-pa­tient study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER